文献速递前列腺癌

前列腺放疗后可能治愈与复发后的自然史:RAPTOR研究

Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR).
PubMed 文献 · Eur Urol Oncol · 2026-10-01

该研究基于11项随机试验的3120例中高危前列腺癌患者数据,分析放疗后5年无生化复发(BCR)与后续远处转移(DM)和前列腺癌特异性死亡(PCSM)风险的关系。结果显示,中危患者单纯高剂量放疗后5年无BCR者预后良好,但需ADT强化治疗者即使5年无BCR仍有较高残留风险;早期BCR(≤5年)与DM和PCSM风险显著升高相关。

要点

  • 中危前列腺癌单纯高剂量放疗后5年无BCR,8年DM和10年PCSM累积发生率低。
  • 中危联合短期ADT或高危联合长期ADT者,5年无BCR后残留转移风险仍超预设阈值。
  • 放疗后5年内出现BCR与远处转移和前列腺癌特异性死亡风险显著升高相关。

核心结论

  • 放疗后5年无BCR对中危前列腺癌单纯放疗者提示良好长期预后,但对需ADT强化治疗者不够。
  • 早期BCR(≤5年)与所有治疗组DM和PCSM风险显著升高相关。

研究设计与样本

  • 事后个体患者数据分析,纳入11项随机试验中3120例中危(89%)或高危(11%)前列腺癌患者,均接受当代高剂量放疗±雄激素剥夺治疗(ADT)。

主要发现

  • 中危患者单纯高剂量放疗后5年无BCR者,8年DM和10年PCSM调整累积发生率分别为6.6%和2.5%。
  • 中危患者高剂量放疗联合短期ADT后5年无BCR者,8年DM调整累积发生率为11%。
  • 高危患者高剂量放疗联合长期ADT后5年无BCR者,8年DM调整累积发生率为16%。
  • 早期BCR(≤5年)在所有治疗组中均与DM和PCSM风险显著升高相关。

关键数值与推荐

  • 预设8年DM和10年PCSM累积发生率≤10%视为有利长期预后。
  • 中危单纯高剂量放疗组8年DM为6.6%、10年PCSM为2.5%,低于阈值。
  • 中危联合短期ADT组8年DM为11%,高危联合长期ADT组为16%,均超过阈值。

临床怎么用

  • 中危前列腺癌单纯高剂量放疗后5年无BCR者可视为可能治愈,后续监测可适当放宽。
  • 接受ADT强化的中危或高危患者,即使5年无BCR仍需警惕远处转移风险,加强随访。
  • 放疗后5年内出现BCR提示高风险,应积极评估和治疗。

局限性

  • 分析为回顾性,各试验BCR定义存在异质性。
  • 缺乏合并症数据和当代风险亚分类。
  • 组成试验处于前列腺特异性膜抗原成像前时代。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether freedom from biochemical recurrence (BCR) at 5 yr after definitive radiotherapy (RT) for localized prostate cancer (PCa) represents a durable cure remains uncertain. OBJECTIVE: To evaluate the association between the timing of BCR after RT and the long-term risks of distant metastasis (DM) and PCa-specific mortality (PCSM), overall and according to treatment intensity, including outcomes by BCR timing (≤5 yr, >5 yr, or no BCR). DESIGN, SETTING, AND PARTICIPANTS: Post hoc individual patient data analysis of 3120 men with intermediate- (89%) or high-risk (11%) PCa enrolled in 11 randomized trials within the Meta-Analysis of Randomized Trials in Cancer of the Prostate consortium and treated with contemporary high-dose RT (HDRT) ± androgen deprivation therapy (ADT). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cumulative incidences of DM at 8 yr and PCSM at 10 yr after RT were estimated using competing-risk methods. Adjusted cumulative incidences were estimated using average marginal effects, accounting for clinicopathologic factors, treatment intensity, and progressively longer durations remaining free of BCR after RT. A priori, cumulative incidences ≤10% were considered indicative of a favorable long-term prognosis. RESULTS AND LIMITATIONS: Among men without BCR at 5 yr, subsequent risks of DM and PCSM were low overall. In patients with intermediate-risk PCa treated with HDRT alone, the adjusted cumulative incidences of 8-yr DM and 10-yr PCSM were 6.6% and 2.5%, respectively, indicating a favorable long-term prognosis based on the prespecified threshold. In contrast, patients with intermediate-risk PCa treated with HDRT plus short-term ADT and patients with high-risk PCa treated with HDRT plus long-term ADT had higher residual metastatic risk (8-yr adjusted cumulative DM incidence of 11% and 16%, respectively) exceeding the predefined favorable prognosis threshold despite remaining BCR-free for 5 yr. Early BCR (≤5 yr) was associated with substantially higher risks of DM and PCSM across all treatment groups. Limitations include the retrospective nature of the analyses, heterogeneity in BCR definitions across trials, absence of comorbidity data and contemporary risk subclassification, and the pre-prostate-specific membrane antigen imaging era of the constituent trials. CONCLUSIONS: A 5-yr BCR-free benchmark was associated with a favorable long-term prognosis for intermediate-risk PCa treated with RT alone, but it appears insufficient for patients requiring ADT intensification. External validation in contemporary cohorts with standardized BCR definitions and modern imaging is warranted.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Roy S, Romero T, Roach M, et al. Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR). Eur Urol Oncol. 2026. PMID: 42823260. doi:10.1016/j.euo.2026.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。